Q2 Earnings Estimate for Biofrontera Issued By Roth Capital

Biofrontera Inc. (NASDAQ:BFRI) – Research analysts at Roth Capital issued their Q2 2025 EPS estimates for Biofrontera in a research note issued to investors on Thursday, November 14th. Roth Capital analyst J. Aschoff forecasts that the company will earn ($0.32) per share for the quarter. The consensus estimate for Biofrontera’s current full-year earnings is ($3.11) per share. Roth Capital also issued estimates for Biofrontera’s Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at $0.12 EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.34 EPS and FY2028 earnings at $0.63 EPS.

Separately, Benchmark reaffirmed a “buy” rating and set a $7.00 target price on shares of Biofrontera in a research report on Friday.

Biofrontera Price Performance

Shares of BFRI stock opened at $0.67 on Monday. The company’s fifty day moving average price is $1.02 and its two-hundred day moving average price is $1.08. The firm has a market capitalization of $3.72 million, a P/E ratio of -0.30 and a beta of 0.50. Biofrontera has a 12 month low of $0.61 and a 12 month high of $4.04.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.